Please vote your proxy online now or by phone by dialing 866-206-4393.
May 13, 2024
8:30 AM ET
You must register to be eligible to participate in the meeting.
Deadline to Register*
May 10, 2024
5:00 PM ET
View an enhanced version of our Annual Report.
View an enhanced version of our Proxy Statement.
You may request paper copies of the proxy materials by phone, email or online. To request by phone dial 866-648-8133.
NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines which can be designed to increase, decrease, or change gene function, as appropriate, to resolve genetic defects that drive disease. NeuBase’s targeted PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the DNA or RNA level by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neuromuscular, neurological and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions.